HC Wainwright Issues Positive Forecast for Eton Pharmaceuticals (NASDAQ:ETON) Stock Price

Eton Pharmaceuticals (NASDAQ:ETON) had its price objective increased by HC Wainwright from $70.00 to $80.00 in a research report sent to investors on Friday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

A number of other research firms have also issued reports on ETON. Weiss Ratings raised shares of Eton Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a research note on Tuesday, September 22nd. Zacks Research raised Eton Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, October 12th. Canaccord Genuity Group increased their price objective on Eton Pharmaceuticals from $60.00 to $68.00 and gave the company a “buy” rating in a research report on Friday, August 14th. B. Riley Financial reiterated a “buy” rating and issued a $70.00 target price (up from $40.00) on shares of Eton Pharmaceuticals in a report on Friday, August 14th. Finally, Craig Hallum restated a “buy” rating and set a $78.00 price target on shares of Eton Pharmaceuticals in a report on Thursday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $77.00.

Eton Pharmaceuticals Stock Up 19.7%

NASDAQ:ETON traded up $9.31 on Friday, reaching $56.46. The stock had a trading volume of 1,269,987 shares, compared to its average volume of 435,252. The stock has a market cap of $1.61 billion, a P/E ratio of 37.39 and a beta of 0.89. Eton Pharmaceuticals has a 12-month low of $14.27 and a 12-month high of $66.37. The company has a current ratio of 1.52, a quick ratio of 1.30 and a debt-to-equity ratio of 0.41. The company has a 50-day moving average of $54.80 and a 200 day moving average of $36.46.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its quarterly earnings results on Thursday, November 5th. The company reported $0.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.31 by $0.19. Eton Pharmaceuticals had a net margin of 12.02% and a return on equity of 40.13%. The business had revenue of $57.93 million during the quarter, compared to analyst estimates of $41.98 million. On average, research analysts predict that Eton Pharmaceuticals will post 1.13 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Paul V. Maier sold 50,000 shares of the company’s stock in a transaction on Friday, August 28th. The stock was sold at an average price of $59.07, for a total transaction of $2,953,500.00. Following the transaction, the director directly owned 59,745 shares of the company’s stock, valued at approximately $3,529,137.15. The trade was a 45.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider David Krempa sold 25,000 shares of the company’s stock in a transaction on Monday, August 24th. The shares were sold at an average price of $65.07, for a total value of $1,626,750.00. Following the transaction, the insider directly owned 37,025 shares in the company, valued at $2,409,216.75. The trade was a 40.31% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 79,166 shares of company stock worth $4,809,672 in the last quarter. 16.49% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Eton Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the business. Hilton Head Capital Partners LLC purchased a new stake in shares of Eton Pharmaceuticals in the third quarter worth approximately $26,000. Toth Financial Advisory Corp acquired a new stake in shares of Eton Pharmaceuticals during the second quarter worth approximately $43,000. Sterling Capital Management LLC boosted its holdings in shares of Eton Pharmaceuticals by 845.7% during the third quarter. Sterling Capital Management LLC now owns 889 shares of the company’s stock worth $46,000 after purchasing an additional 795 shares during the period. USA Financial Formulas purchased a new position in Eton Pharmaceuticals during the third quarter valued at approximately $62,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in Eton Pharmaceuticals during the third quarter valued at approximately $75,000. Hedge funds and other institutional investors own 27.86% of the company’s stock.

More Eton Pharmaceuticals News

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: Q3 product sales reached a record $57.9 million, up 158% year over year. Eton reported diluted GAAP EPS of $1.06 and non-GAAP EPS of $0.50, and said it exceeded a $200 million annualized revenue run rate five quarters ahead of schedule. Eton Q3 results
• Positive Sentiment: Management raised its 2026 revenue outlook to more than $175 million, from more than $145 million, and lifted its adjusted EBITDA margin outlook to above 40%, from above 35%. The stronger forecast reinforces expectations for continued growth and improving profitability. Eton earnings and guidance
• Positive Sentiment: Canaccord Genuity and HC Wainwright both raised their price targets to $80 and maintained Buy ratings, signaling confidence in Eton’s prospects. Canaccord Genuity rating HC Wainwright rating
• Neutral Sentiment: Eton announced preliminary results from an ET-700 pilot study assessing copper absorption inhibition and gastrointestinal tolerability. The brief report does not provide enough detail to judge the findings’ significance for the pipeline. ET-700 pilot study update

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with limited therapeutic options. The company generally pursues products that address unmet medical needs, including medicines for pediatric and orphan indications.

Eton’s commercial portfolio has included Alkindi Sprinkle, an oral hydrocortisone formulation used as replacement therapy in young children with adrenal insufficiency, and Eprontia, an oral solution formulation of topiramate.